{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:44:11Z","timestamp":1792788251090,"version":"4.5.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The \u201cDengfeng\u201d Talent Training Program of Beijing Hospitals Authority","award":["DFL20240301"],"award-info":[{"award-number":["DFL20240301"]}]},{"name":"Funds from the Chinese Institutes for Medical Research, Beijing"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01718-x","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T07:40:32Z","timestamp":1750146032000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Menin inhibitors from monotherapies to combination therapies: clinical trial updates from 2024 ASH annual meeting"],"prefix":"10.1186","volume":"18","author":[{"given":"Gejia","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Hu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"1718_CR1","unstructured":"Aldoss I, Issa GC, Blachly JS, Thirman MJ, Mannis GN, Arellano ML et al. Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R\/R) KMT2Ar Acute Leukemia. Oral session presented at: 66th Annual Meeting of the American Society of Hematology; 2024 Dec 7\u201310; San Diego. https:\/\/cms.syndax.com\/wp-content\/uploads\/2024\/10\/Aldoss_2024-ASH_AUGMENT-101-Ph2-KMT2Ar-Updated_Oral_Final.pdf"},{"key":"1718_CR2","doi-asserted-by":"crossref","unstructured":"Loo S, Iland H, Tiong IS, Westerman D, Othman J, Marlton P et al. Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in NPM1 mutated or KMT2A-rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform Trial. Oral session presented at: 66th Annual Meeting of the American Society of Hematology; 2024 Dec 7\u201310; San Diego. Revumenib as Pre-emptive Therapy for Measurable Residual Disease in NPM1 Mutated or KMT2A-rearranged AML: A Domain of The Multi-Arm ALLG AMLM26 INTERCEPT Platform Trial. https:\/\/cms.syndax.com\/wp-content\/uploads\/2024\/12\/Loo_2024-ASH_INTERCEPT_Oral_Final.pdf","DOI":"10.1182\/blood-2024-202895"},{"key":"1718_CR3","doi-asserted-by":"crossref","unstructured":"Searle E, Recher C, Abdul-Hay M, Abedin S, Aldoss I, Pierola AA et al. Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed\/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations. Oral session presented at: 66th Annual Meeting of the American Society of Hematology; 2024 Dec 7\u201310; San Diego. https:\/\/www.jnjmedicalconnect.com\/media\/attestation\/congresses\/oncology\/2024\/ash\/bleximenib-dose-optimization-and-determination-of-rp2d-from-a-phase-1-study-in-relapsedrefractory-ac.pdf","DOI":"10.1182\/blood-2024-207106"},{"issue":"Supplement 1","key":"1718_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1182\/blood-2024-194827","volume":"144","author":"JF Zeidner","year":"2024","unstructured":"Zeidner JF, Yuda J, Watts JM, Levis MJ, Erba HP, Fukushima K, et al. Phase 1 results: First-in-Human phase 1\/2 study of the Menin-MLL inhibitor Enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia. Blood. 2024;144(Supplement 1):213.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1718_CR5","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1182\/blood-2024-198959","volume":"144","author":"D Wu","year":"2024","unstructured":"Wu D, Wang Y, Chen S, Li Y, Huang R, Ren J, et al. A First-in-Human phase 1\/2 study of the Menin-KMT2A(MLL1) inhibitor BN104 in adult patients with relapsed or refractory acute leukemia. Blood. 2024;144(Supplement 1):2879.","journal-title":"Blood"},{"key":"1718_CR6","doi-asserted-by":"crossref","unstructured":"Issa GC, Cuglievan B, Daver N, DiNardo CD, Farhat A, Short NJ et al. Phase I\/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine\/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R\/R AML. Oral session presented at: 66th Annual Meeting of the American Society of Hematology; 2024 Dec 7\u201310; San Diego. https:\/\/cms.syndax.com\/wp-content\/uploads\/2024\/12\/Issa_2024-ASH_SAVE_Oral_Final.pdf","DOI":"10.1182\/blood-2024-204375"},{"key":"1718_CR7","doi-asserted-by":"crossref","unstructured":"Fathi AT, Issa GC, Wang ES, Erba H, Altman JK, Balasubramanian SK et al. Ziftomenib Combined with Venetoclax\/Azacitidine in Relapsed\/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007. Poster session presented at: 66th Annual Meeting of the American Society of Hematology; 2024 Dec 7\u201310; San Diego. https:\/\/kuraoncology.com\/wp-content\/uploads\/POSTER-PDF-2880_Fathi_ASH-KOMET-007-Relapsed-Refractory-Poster_12Nov2024_FINAL.pdf","DOI":"10.1182\/blood-2024-199170"},{"key":"1718_CR8","doi-asserted-by":"crossref","unstructured":"Recher C, O\u2019Nions J, Aldoss I, Pierola AA, Allred A, Alonso-Dominguez JM et al. Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations. Oral session presented at: 66th Annual Meeting of the American Society of Hematology; 2024 Dec 7\u201310; San Diego. https:\/\/www.jnjmedicalconnect.com\/media\/attestation\/congresses\/oncology\/2024\/ash\/phase-1b-study-of-meninkmt2a-inhibitor-bleximenib-in-combination-with-intensive-chemotherapy-in-newl.pdf","DOI":"10.1182\/blood-2024-207072"},{"key":"1718_CR9","doi-asserted-by":"crossref","unstructured":"Zeidan AM, Wang ES, Issa GC, Erba H, Altman JK, Balasubramanian SK et al. Ziftomenib Combined with Intensive Induction (7\u2009+\u20093) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007. Oral session presented at: 66th Annual Meeting of the American Society of Hematology; 2024 Dec 7\u201310; San Diego. https:\/\/kuraoncology.com\/wp-content\/uploads\/ASH_2024_KOMET-007_Oral-Presentation.pdf","DOI":"10.1182\/blood-2024-198218"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01718-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01718-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01718-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T07:40:38Z","timestamp":1750146038000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01718-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":9,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1718"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01718-x","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]},"assertion":[{"value":"30 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"63"}}